Bavarian Nordic ( ) - 株価, ニュースと分析XTRA:BV3

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

BV3 株式概要

Develops, manufactures, and commercializes life-saving vaccines.

BV3 ファンダメンタル分析
スノーフレーク・スコア
評価	5/6
将来の成長	0/6
過去の実績	2/6
財務の健全性	6/6
配当金	0/6

報酬

当社が推定した公正価値より60.1%で取引されている

今年は黒字化を達成

同業他社や業界と比較して、良好な取引価格

リスク分析

今後3年間の収益は年平均16.8%減少すると予測されている。

高いレベルの非現金収入

株式の流動性は非常に低い

過去1年間で株主の希薄化が進んだ

Bavarian Nordic A/S 競合他社

Formycon

XTRA:FYB

€950.1m

Biotest

XTRA:BIO3

€1.4b

2invest

XTRA:2INV

€53.5m

Dermapharm Holding

XTRA:DMP

€1.9b

価格と性能

の歴代最高値、変動、値下がりまとめBavarian Nordic
過去の株価
現在の株価	DKK 25.30
52週高値	DKK 35.80
52週安値	DKK 23.12
ベータ	1.29
11ヶ月の変化	0%
3ヶ月変化	-3.80%
1年変化	-12.61%
33年間の変化	n/a
5年間の変化	n/a
IPOからの変化	-58.71%

Recent updates

株主還元

	BV3	DE Biotechs	DE 市場
7D	0%	-1.8%	-0.1%
1Y	-12.6%	-18.5%	2.4%

業界別リターン: BV3過去 1 年間で-22.4 % の収益を上げたGerman Biotechs業界を上回りました。

リターン対市場: BV3は、過去 1 年間で2.4 % のリターンを上げたGerman市場を下回りました。

価格変動

Is BV3's price volatile compared to industry and market?
BV3 volatility
BV3 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.6%

安定した株価: BV3過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: 過去 1 年間のBV3のボラティリティの変化を判断するにはデータが不十分です。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1992	1,354	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S 基礎のまとめ

Bavarian Nordic の収益と売上を時価総額と比較するとどうか。
BV3 基礎統計学
時価総額	€1.44b
収益（TTM）	€144.27m
売上高(TTM)	€741.69m

10.0x

PER（株価収益率

1.9x

P/Sレシオ

BV3 は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
BV3 損益計算書（TTM）
収益	DKK 5.53b
売上原価	DKK 1.84b
売上総利益	DKK 3.69b
その他の費用	DKK 2.62b
収益	DKK 1.08b

直近の収益報告

Jun 30, 2023

次回決算日

Nov 16, 2023

一株当たり利益（EPS）	13.84
グロス・マージン	66.78%
純利益率	19.45%
有利子負債／自己資本比率	0.2%

BV3 の長期的なパフォーマンスは？

過去の実績と比較を見る

BV3 株式概要

報酬

リスク分析

Bavarian Nordic A/S 競合他社

XTRA:FYB

€950.1m

XTRA:BIO3

€1.4b

XTRA:2INV

€53.5m

XTRA:DMP

€1.9b

価格と性能

最新ニュース

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Recent updates

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold €68k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings released: kr.3.40 loss per share (vs kr.2.40 loss in 2Q 2021)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

First quarter 2022 earnings released

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Executive Officer Tommi Kainu has left the company

High number of new directors